GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biophytis ALBPS.PA · EUR

Health Care · Euronext Paris · 🇫🇷 France

Compare

0.04

+5.90%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Biophytis

Its shares trade on Euronext Paris under the ticker ALBPS.PA. It has been listed since 13 July 2015.

Biophytis SA is a holding company, which engages in the clinical development of therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
13 Jul 2015
Employees
22

Leadership

Pay as last reported

  • Mr. Stanislas VeilletChairman of the Board, Chief Executive Officer, since 2015€453,000
  • Mr. Nicolas FellmannChief Financial Officer
  • Mr. Jean MarianiDirector, since 2021€77,000
  • Mr. Claude AllaryIndependent Director€40,000
  • Mrs. Nadine CoulmIndependent Director€40,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Biophytis SA focuses on clinical development of therapeutics for sarcopenia and ARMD in the Health Care sector.
  • The company has two drug candidates, Sarconeos (BIO101) and Macuneos (BIO201), in clinical development.
  • Biophytis SA conducts simultaneous clinical trials in the United States and domestic market.

Weaknesses

  • Biophytis SA employs only 22 full-time employees, limiting resource capacity.
  • The company's clinical development stage may face delays in regulatory approvals.
  • Biophytis SA's focus on aging diseases may restrict market expansion opportunities.

Opportunities

  • The growing global market for aging-related treatments presents significant opportunities.
  • Biophytis SA can expand its clinical trials to additional regions beyond the US and France.
  • Increasing demand for biotechnology solutions in the Health Care sector offers growth potential.

Threats

  • Competition from established biotechnology firms in the Health Care sector.
  • Regulatory challenges in the United States and France could delay drug approvals.
  • Economic downturns may reduce funding for clinical development projects.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.